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Introduction 
The “Opioid Crisis” is a bit of a misnomer.  That there was a single peak in opioid 
abuse in American History is false; in fact, abuse of opioids has had many faces ranging 
from types of opiate drugs to opioid replacement medications, the dependency upon 
which has ebbed and flowed in ongoing waves that the American government, medical 
professionals, and insurance companies combat to this day.  A more apt description of 
this social phenomenon is perhaps the opioid epidemic.  The terminology surrounding 
opioid dependency is always bound by some temporal limit, however, opioid dependency 
remains an ongoing problem that has not seen any significant resolution to date.  
Real social cognizance of opioids as a problem to acknowledge and target emerged 
in the early 1970’s, with the adoption of the Controlled Substances Act, which classified 
types of opioids and regulated them according to their classification.1  However, large-
scale addiction to opioids dials back to the civil war era, when soldiers became dependent 
on  the morphine their pain was treated with.2  This highlights a key aspect of the 
phenomenon that is the opioid epidemic: much of addiction historically and continually 
buds from medicinal uses of opioids, and an ongoing effort to market new forms of 
opioids (from morphine, to heroin, to oxytocin) as “safer” to use for temporary medicinal 
purposes.3  As a result, we are met in the modern day with a conundrum. If opioid 
 
1 https://www.georgetownbehavioral.com/node/2013 
2 https://www.georgetownbehavioral.com/node/2013 
3 https://www.georgetownbehavioral.com/node/2013  
  
replacement medications are a provenly effective means to combat opioid addiction, how 
must they be regulated so as to not advance the cycle of treatment and dependency on 
treatment?  This conundrum is in turn met with the social and economic realities of 
modern American society; access to healthcare and treatment can be inherently classist, 
and with a large percentage of opioid users being of the lower working class, opioid 
treatment in the form of replacement therapy is at an apparent road block.  Road blocks 
preventing access to opioid treatment medications come in many forms, some through 
marketing schemes, others present in legislation, and most exist in exorbitantly long 
application processes required by insurance providers and medical professionals, which 
by their nature isolate certain communities of whom are the largest percentage of opioid 
users.  
A Look into the Past and Present of Opioid Addiction and Treatment 
 After morphine was introduced in the 1860’s as a means to treat wounded civil 
war soldiers, dependency quickly became a problem, spiraling into mass addiction.  
According to Journal of the Civil War Era, “Opium Habit, published in 1868, Horace B. 
Day estimated that 80,000 to 100,000 Americans were addicted to op ium.” 4  This was the 
largest and first real drug epidemic to strike America. 5 “Maimed and shattered survivors 
from a hundred battle-fields,” Horace B. Day wrote, “diseased and disabled soldiers 
released from hostile prisons, anguished and hopeless wives and mothers, made so by the 
slaughter of those who were dearest to them, have found, many of them, temporary relief 
 
4 https://www.journalofthecivilwarera.org/2016/11/civil-war-veterans-opiate-addiction-
gilded-age/ 
5 https://www.journalofthecivilwarera.org/2016/11/civil-war-veterans-opiate-addiction-
gilded-age/ 
 
  
from their sufferings in opium.”6  The addiction wasn’t contained to the soldiers and 
quickly spread to society at large. At the bud of opiate addiction, the majority of 
consumers and abusers proved to be mostly Southern, white individuals.7 
 In 1898, Bayer Company, now a pharmaceutical giant, introduced heroin into 
mainstream commerce where it was largely marketed and regarded as a “wonder drug.” 8  
With its commercial accessibility, heroin became widely abused, especially when people 
realized its effects were maximized by injection.9  This incited a federal response that 
came in the form of The Harrison Narcotics Act which taxed the importing, producing, 
distributing, and dispensing of narcotics.10  This marked a developing social awareness to 
the addictive nature of narcotics and opiates, and so developed the stigma against users as 
doctors refused to treat those addicted to narcotics. 11 In 1924, heroin was finally 
outlawed. 12  
The 70’s were notorious for drug consumption, with cultural markers like 
Woodstock and a later punk and early grunge era glamorizing the use of many drugs, 
ranging from psychedelics to narcotics.  The 70’s was the start of a major opioid 
epidemic, which morphed into a crack epidemic in the 80’s and reared its head once again 
in the 90’s when Purdue Pharma began testing and finally released OxyContin in 1996.13 
 
6 Horace B. Day, The Opium Habit (New York: Harper & Brothers, 1868), 6-7 
7 Id.  
8 https://www.cnn.com/2016/05/12/health/opioid-addiction-history/index.html 
9 Id. 
10 https://www.journalofthecivilwarera.org/2016/11/civil-war-veterans-opiate-addiction-
gilded-age/#_ftn5 
11 Ibid.  
12 Id.  
13 https://www.cnn.com/2016/05/12/health/opioid-addiction-history/index.html 
  
Marcia L. Meldrum, PhD, writes on Purdue Pharm’s OxyContin that “Purdue’s 
aggressive marketing of its controlled-release opioid Oxycontin as safe for chronic pain 
intersected with the trafficking of cheap, very pure heroin in smaller cities across the 
West, Midwest, and Appalachia. Purdue advertised OxyContin as nonaddictive because 
the drug was released within the body over 12 hours; recreational users quickly learned to 
get high by crushing or dissolving the pills, or simply taking very high doses.”14  Existing 
evidence shows that individuals at greatest risk for prescription opioid overdose include:  
• White and American Indian/Alaska Native people  
• Men (although overdose among women is on the rise)  
• People living in rural areas (clusters in the Southeast—especially in the 
Appalachian region)  
• Adults aged 45-54 years  
• People who obtain multiple controlled substance prescriptions (especially 
the combination of opioid analgesics and benzodiazepines) from multiple 
providers  
• People who take high daily dosages of opioid pain relievers15 
The National Capital Poison Center and Poison Control reports of the 90’s that 
“during this time, pharmaceutical companies also began to promote the use of opioids in 
patients with non-cancer related pain even though there was a lack of data regarding the 
risks and benefits in these patients. By 1999, 86% of patients using opioids were  using 
them for non-cancer pain. Communities where opioids were readily available and 
prescribed liberally were the first places to experience increased opioid abuse and 
diversion (the transfer of opioids from the individual for whom they were prescribed, to 
 
14 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940677/ 
15 https://aspe.hhs.gov/system/files/pdf/107956/ib_OpioidInitiative.pdf 
 
  
others, which is illegal)”16  This eventually led to a slew of public and legal backlash 
against the Sackler family, who control Purdue Pharma and were blamed for much of the 
addiction and death resulting from OxyContin marketing.   
 The New York Times writes of “lawsuits filed by the attorneys general of 
Massachusetts and New York,” cases which “lay out the extensive involvement of a 
family that has largely escaped personal legal consequences for Purdue Pharma’s role in 
an epidemic that has led to hundreds of thousands of overdose deaths in the past two 
decades,” after years of investigation.17 The Sackler family involvement in profiting from 
addiction took a sickening form in the mid-2000’s, a new business endeavor called 
“Project Tango.”  Details of Project Tango emerged from the Massachusetts and New 
York attorneys general lawsuits.  “Pain treatment and addiction are naturally linked,” one 
Project Tango document, included in the New York complaint (The People v. Purdue 
Pharma, linked herein), said.  It depicted a big blue funnel. The fat end was labeled “pain 
treatment”; the narrow end was labeled “opioid addiction treatment.” The company, the 
document said, could make money at both ends of the funnel as an “end -to-end pain 
provider.”18  
The prospect that the Sackler family, with an estimated 13 billion dollars in 
personal fortune, could profit off replacement medications that address the addiction and 
mortality risk they’ve allegedly caused is chilling.19  The New York Times reports that 
 
16 https://www.poison.org/articles/opioid-epidemic-history-and-prescribing-patterns-182 
17 https://www.nytimes.com/2019/04/01/health/sacklers-oxycontin-
lawsuits.html?section=Health 
18 Id. (quoting, The People of the State of New York v. Purdue Pharma at  
https://ag.ny.gov/sites/default/files/oag_opioid_lawsuit.pdf) 
19 Id. 
  
“Since OxyContin came on the market, more than 200,000 Americans have died of 
overdoses related to prescription opioids.”  A 2001 email included in the documents in 
the Massachusetts case catches Richard Sackler  stating “we have to hammer on abusers 
in every way possible… they are the culprits and the problem. They are reckless 
criminals.”20  
 The stigmatization of users and abusers as criminal or untreatable echoes the 20’s 
rhetoric when doctors refused to treat narcotics users.  There is a sort of cycle where 
opioids are marketed and distributed by providers and companies, but users are then 
criminalized for problems developed from misuse of those very products.  The vacuum 
between them is a major social issue, and the gaslighting of American society and opioid-
addicted individuals themselves to reframe their victimhood as controlled criminal 
actions serves as a barrier to treatment.  This is not to say that there are no treatment 
options available for users and abusers of opioids.  In fact, there are a number of methods 
ranging from rehabilitation programs to replacement drugs meant to wean individuals off 
of the drugs.  However, access to such treatment proves to be complex, between 
economic barriers, system guideline barriers, and a low morale amongst users .  
Treatment Options and Replacement Medications 
 Attempts to curb the epidemic and prevent opioid-related deaths took on many 
structural forms.  Adoption of Prescription Drug Monitoring Programs (“PDMP”), 
allowed for healthcare providers to closely monitor their patients’ use of prescribed 
opioids, including tracking other providers’ prescriptions to their patients.  Because 
 
20 https://www.nytimes.com/2019/04/01/health/sacklers-oxycontin-
lawsuits.html?section=Health 
 
  
PDMPs are computer programs, they are highly efficient, relatively affordable, and can 
allow interstate monitoring of patients.21  Interstate monitoring can not only allow 
protection of individuals but helps in preventing cross-state trafficking of prescription 
opioids.22  This method, however, only helps to identify high risk individuals.23  The 
introduction of opioid-specific guidelines for individuals with chronic pain also helps 
medical providers by establishing dosage requirements and caps.  Although little research 
is available as to the benefit of these guidelines, it reflects a systemic  effort to combat 
opioid abuse.24  
 One of the most provenly effective methods to combatting the opioid epidemic is 
Medication-assisted Treatment, or MAT.  Mat includes the use of medications to slowly 
decrease opioid and other substance intake amounts and rates with the goal of both 
reducing overdose and death and slowly rehabilitating addicts. 25  MAT is often combined 
with other rehabilitative measures like counseling and therapy and is more a process for 
recovery assisted by medication than a simple replacement, as is often assumed.  “Studies 
have shown that the most effective treatments for opioid use disorders are those that 
include a set of comprehensive medical, social, psychological and rehabilitation services 
that address all the needs of the individual.”  The medications most commonly used in 
MAT are buprenorphine, methadone, and extended-release naltrexone (which, in its non-
extended-release form, is also used to reverse the effects of opioid overdose).26  These 
 
21 https://aspe.hhs.gov/system/files/pdf/107956/ib_OpioidInitiative.pdf (“What Works”)  
22 Id.  
23 Id. 
24 Id. 
25 Id. 
26 Id.  
  
medications work by precipitating withdrawal symptoms to avoid relapse.  Although many 
studies indicate that MAT is an effective, if not the most effective, treatment method for 
opioid users, it is only used by approximately 1 out of 2.5 million Americans who would 
benefit from it.27  This beckons the question of why more people don’t use this method if 
it’s one of the best.  
 The first reason is the risk of diversion.  Because medications like buprenorphine 
and methadone work to combat withdrawal symptoms, and in fact are used by a majority 
of users for therapeutic purposes , they are regarded as “replacing” opioid alternatives, the 
dependence on which is often actually an avoidance of withdrawal symptoms.28  They, 
therefore, are feared to pose a risk of dependency.  The fear is essentially that people who 
previously misused opioids (misused meaning used outside of prescribed methods and 
amounts or without prescription) may find themselves leaning heavily on medications 
like buprenorphine and methadone in ways they would have their  opioids.  
However, reports show that most patients being treated for opioid addiction do not 
rank buprenorphine as their “primary drug of misuse.”29  There is a minority percentage 
of individuals (about 8-25%) who misuse buprenorphine, a minority that has been 
decreasing over time as a result of buprenorphine’s dissimilar, less rewarding effects. 30  
 
27 Id. at Page 6 
28 Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone 
among injecting and noninjecting opioid users. J Addict Med. 2011;5(3):175-180. 
doi:10.1097/ADM.0b013e3182034e31 
29 National Institute on Drug Abuse, quoting Cicero TJ, Surratt HL, Inciardi J. Use and 
misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 
2007;3(6):302-308. 
30 Id.  
 
  
Most fear of diversion has to do with methadone, which has higher rates of overdose.  
However, these rates correlate directly to the purpose of the prescription: most people 
who overdose on methadone are being prescribed methadone for pain, not as a form of 
substance abuse treatment.31  The individuals who use methadone as part of their MAT 
plan make up the stark minority of those who overdose or showcase diversion 
symptoms.32 
Access to Treatment 
A. Who’s Addicted and How MAT Medications are Classified by Medicaid  
According to the National Institute on Drug Abuse, an estimated 2.1 million 
people in the United States had a substance use disorder related to prescription opioid 
pain medicines in 2016.33  However, only about 17.5 percent of people with prescription 
opioid use disorders received specialty treatment.34  So who are the individuals who 
currently have substance abuse disorder and are addicted to opioids?   
“According to the NSDUH, of the 10 States with the highest reported rates of past 
year nonmedical pain reliever use within the total population aged 12 or older, 7 out of 10 
were in the Western region of the United States (Arizona, Colorado, Idaho, Nevada,  New 
Mexico, Oregon, and Washington).  And, of the States with the lowest rates of past year 
nonmedical pain relievers, 4 were in the Midwest region (Illinois, Iowa, North Dakota, 
and South Dakota).  Within states and regions, illicit use of pain relievers differs 
 
31 Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from 
methadone used for pain relief - United States, 1999-2010. 
32  Id.  
33 https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-
addiction/overview 
34 Id. 
  
substantially by the urban/rural characteristics of the population in the state/region.   
Interestingly, NSDUH respondents in smaller metropolitan areas reported the highest rate 
of illicit use of pain relievers (5.4%), while rural areas reported the lowest rate of use 
(3.5%).  However, research studies that focus specifically on adolescents have suggested 
that for this at-risk population group use rates of illicit pain relievers are higher in rural 
areas.”35 
According to the Nation Institute on Drug Abuse, 
• Roughly 21 to 29 percent of patients prescribed opioids for chronic pain 
misuse them.  
• Between 8 and 12 percent develop an opioid use disorder.  
• An estimated 4 to 6 percent who misuse prescription opioids transition 
to heroin.  
• About 80 percent of people who use heroin first misused prescription 
opioids.  
• Opioid overdoses increased 30 percent from July 2016 through 
September 2017 in 52 areas in 45 states.  
• The Midwestern region saw opioid overdoses increase 70 percent from 
July 2016 through September 2017.  
• Opioid overdoses in large cities increase by 54 percent in 16 states36 
 
Although no one is immune to the addictive quality of opioids, the largest increase 
in overdose deaths affects relatively young people, particularly men, from their 20s to 
40s.37 “Fringe metro and micropolitan areas see the highest rates of addiction and death.  
The states with highest rates of death fall mostly on the eastern side of the US – New 
 
35 https://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-
addiction-treatment_final 
36 https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis 
37 https://www.rehabspot.com/opioids/opioid-epidemic/ 
 
  
Hampshire, West Virginia, Massachusetts, and Ohio.”38  The large majority of those 
impacted by addiction and overdose from opioids are white, working class people, and 
this is perhaps because white people are more readily prescribed medications for pain.39  
“Medicine has a long, unsavory history of expecting people of color to tolerate larger 
levels of pain,” said Dr. Steven Woolf of Virginia Commonwealth University.   Since a 
large percentage of those addicted to opioids’ addiction began with prescription pain 
killers, which are often prescribed to individuals with chronic pain , the demographic 
makes some sense with Dr. Woolf’s comments in mind.  Another contributor may be 
implicit physician biases that white individuals may be less l ikely to “abuse” drugs or 
engage in criminal acts, like distributing drugs to others, and a greater willingness to 
entrust those individuals with more addictive substances.   
 Although a large percentage of those suffering from substance abuse disorders 
actually go untreated, those who are treated tend to be covered by Medicaid and Medicare 
(government affordable care programs) because of their socioeconomic status.  Medicaid 
programs tend to vary by state, however they have historically proven to pose various 
barriers in access to MAT and other treatments.  While most states have chosen to 
provide some type of addiction treatment under Medicaid, many have taken a long time to 
(and still do not) reflect modern effective means of treatment, like MAT.40  
 
38 https://www.rehabspot.com/opioids/opioid-epidemic/ 
39 Kaiser Health News: https://khn.org/morning-breakout/how-unconscious-physician-
biases-about-race-ethnicity-and-pain-plays-a-role-in-the-opioid-crisis/ 
40 https://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-
addiction-treatment_final 
 
  
Additionally, regional improper use of opioids, particularly prescription opioids, 
correlates to the associated geographic need for healthcare in the form of MAT and other 
forms of substance abuse treatment.41  “It is also worth noting that even amongst addicted 
individuals who are employed or have substantial incomes, as opioid dependence 
progresses, those incomes may cease and subsequently these once-covered or self-pay 
addicted patients may have to rely on public funding including Medicaid in order to 
access addiction treatment and health care if they can.”42 
Where Medicaid programs may cover forms of treatment and counseling, there are 
an array of rules and criteria that must be met in order for medication or treatment 
services to be covered.43 Opioid dependence treatment coverage in particular (especially 
in the form of MAT) demands a strict criteria be met, including “documented patient 
compliance with counseling.”44  
Historically, coverage has been limited to detoxification and short-term 
rehabilitation of those suffering from substance abuse disorders.45 However, some 
common medications used to treat substance abuse disorders have found their way into 
the Medicaid market, though in ways that limit their actual availability.46 Methadone, for 
example, though included in many Medicaid plans is often not fully covered.47 
Additionally, “medicaid coverage of buprenorphine is usually as a pharmacy benefit, 
 
41 Id. 
42 Id. 
43 Id. 
44 Id. at page 7. 
45 Id. 
46 Id. 
47 Id. 
 
  
either under Medicaid FFS or via Medicaid managed care plans contracted with the state 
Medicaid agency.”48  
Injectable Naltrexone, on the other hand, is treated as a “medical benefit” not a 
“pharmacy benefit.” Medical Benefits include physician-administered and/or injectable 
medications, while pharmaceutical benefits are usually patient-administered. Because of 
this, many Practitioners are not aware of injectable naltrexone’s existence because it is 
not listed as a pharmaceutical benefit. This poses a few issues; since injectable 
Naltrexone is the primary medication used to treat on-spot overdose, it is essential for 
those who may be verging on opioid addiction. With the rates of addiction to use be ing so 
high, it would make sense to have access to the antidote to the poison, so to speak. 
However, many recipients may not have both types of coverage which limits their access 
from the already limited selection of the three main medications used in MAT,  and 
further limits ability to treat any potential overdose symptoms. 
B. Lock-In Programs; A Barrier or a Tool? 
Lock-In programs was established within the last decade or so by the Division of 
Medical Services as a means to keep individuals from excessive intake of opioid-
replacement drugs.49 The way it works is a patient is “locked-in” to a particular pharmacy 
or provider who can monitor their medication consumption and make sure it doesn’t 
exceed usual amounts. While Lock-In programs at face value seem to be geared towards 
 
48 Id. 
49 Executive Office of Health and Human Services, 
http://www.eohhs.ri.gov/ProvidersPartners/ProviderManualsGuidelines/MedicaidProvider
Manual/Pharmacy/PharmacyLock-InProgram.aspx 
  
protecting individuals from becoming addicted to the MAT medications, they also serve 
to curb diversion, or pharmacy-hopping for the purpose of selling the opioid 
replacements. However, they also serve to identify individuals at risk for abusing MAT 
medications and restrict their access to those medications.50 “For years, states have been 
establishing and augmenting effective “lock-in” programs that require Medicaid enrollees 
who are “at-risk” for misusing or abusing opioids to use only one pharmacy and/or get 
prescriptions from only one medical office. The Comprehensive Addiction and Recovery 
Act of 2016 (CARA) provides CMS with the authority to allow Medicare Part D plans to 
implement similar pharmacy and prescriber lock-in programs. For both Medicaid 
programs and Medicare Part D plans, lock-in programs are an additional tool to promote 
better coordination between providers and beneficiaries who meet the guidelines for lock-
in.”51 However, the computerized process does not detract from the exorbitant amounts of 
documentation and criteria that must be met, and the strict rules placed on individuals. 
The lock-in program can result in denial of medication to beneficiaries, or denial of 
medications for circumstantial reasons like pregnancy (which may not be negatively 
impacted by the use of MAT medications, and in fact can have much better results on 
pregnancy than cold-turkey withdrawal). Regardless of the algorithm for lock-in 
 
50 U.S. National Library of Medicine National Institutes of Health, Evaluation of a 
Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No 
Impact on Opioid Overdose Risk, Naumann RB. 
 
51 https://www.hhs.gov/about/agencies/asl/testimony/2018-04/tracking-opioid-and-
substance-use-disorders-medicare-medicaid-hhs-programs.html 
  
programs, there will always be outliers who are misjudged as at-risk, and denied access to 
much needed medication.  
 
C. Pre-Authorization: The Biggest Barrier 
One of the most significant barriers to access to opioid-treatment medications is 
the Pre-Authorization Process required by many Medicaid programs. Currently, 
approximately 44 states require pre-authorization for the 3 FDA approved opioid 
treatment drugs, Buprenorphine, Methadone, and Naltrexone.52 Pre-authorization is 
essentially a process required by Medicaid programs prior to administration of opioid 
replacement or treatment drugs (MAT medications). The pre-authorization process differs 
from state to state depending on its Medicaid program, and some Pre-Authorization 
programs require a counseling program or session prior to issuance of the MAT 
medication. Issues arise when that same Medicaid program that requires counseling for 
Pre-authorization or reauthorization would offer minimal counseling coverage.53 The 
counseling and other Pre-Authorization measures often require extensive detail and 
document submission.54 The process, whether or not counseling is involved, often takes a 
number of weeks to process, which is time precious to at-risk patience who may suffer 
relapse, overdose, or even death in that time.55 
 
52 Id. 
53 https://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-
addiction-treatment_final 
54 Id. 
55 Id. 
  
 The American Society of Addiction Medicine writes on injectable Naltrexone, “. . 
. if the injectable naltrexone is covered as a Medicaid pharmaceutical benefit . . . 
adjudication and approval of the medication is much more rapid and electronic, often 
taking 24 hours or less if requirements (edits) are met. However, substantial prior 
authorization requirements may also be embedded in the electronic approval process. 
Counseling may be dealt with separately under medical benefits. Documentation of 
"patient is enrolled in approved substance use disorder therapy" may also be required 
during preauthorization and repeated in reauthorization in order for the treatment plan 
and the medication involved to be approved.”56 Even in attempts to expedite the approval 
process for medications such as injectable Naltrexone, the pre-authorization elements 
remains a time-consuming variable. Furthermore, where Naltrexone may be listed as a 
medical benefit rather than a pharmaceutical one, access would be subject to a whole 
separate prior authorization process through the practitioner, medical group, or hospital, 
since the medication would not be available on a drug list.57 “The data available from the 
survey and from secondary sources indicate that 20 states require prior authorization for 
injectable naltrexone, 11 states do not appear to require prior authorization and 20 states 
had no information available on prior authorization requirements for this alcohol and 
opioid dependence medication as a component of addiction treatment”58 
 The American Society of Addiction Medication, partnered with NIDA (National 
Institute on Drug Abuse), SAMHA (Center for Substance Abuse treatment of the 
Substance Abuse and Mental Health Services Administration), ONDCP (Office of 
 
56 Id. 
57 Id. 
58 Id. 
  
National Drug Control Policy), and OASH (Office of the Assistant Secretary for Health 
of the US Department of Health and Human Services) write an astute analysis regarding 
preauthorization as a barrier. In its project, AMSAM includes the following sample pre-
authorization form: 
“Injectable naltrexone (Vivitrol) may be approved for the prevention of relapse to opioid 
dependence following detoxification when the individual:  
1. Is being treated for opioid dependence; AND  
2. Has had an initial response and tolerates oral naltrexone (Revia) but is unable to 
comply with daily dosing; AND  
3. Has successfully completed an opioid detoxification program; AND  
4. Has been opioid-free (including buprenorphine and methadone) for at least 7 
days prior to initiating treatment with naltrexone (Vivitrol) injection; AND  
5. Actively participates in a comprehensive rehabilitation program that includes 
psychosocial support; AND  
6. Patient has none of the following:  
a. Currently on opioid analgesics for pain management; OR  
b. Currently in acute opioid withdrawal;  
c. A positive urine screen for opioids; OR  
d. A failed naloxone challenge test; OR  
e. Acute hepatitis;  
  
f. Liver failure; OR 
g. Previous hypersensitivity to naltrexone, 75:25 polyactide-co-glycolide 
(PLG), carboxymethylcellulose or any other component of the diluent.”  
 Of particular interest here is the utterly equivocal language used. That pre-
authorization “may” be approved, should applicant “successfully” meet requirements 
shows that meeting the elements is discretionary depending on the program, 
administration method, location, and other subjective variables, and that even should the 
applicant be deemed “successful,” they “may” nonetheless be denied authorization. This 
is emphasized when “in describing preauthorization the plan states ‘[p]reauthorization 
requirements are subject to change at any time and without notice” and “[i]f 
preauthorization for a particular service or treatment is denied, you may be held 
financially responsible for the expense of the test, equipment, service or procedure. ’”59 
The very nature of the pre-authorization form denies the reality of the applicant, who is 
as discussed prior, most likely working-class fringe-metro or otherwise rurally located, 
may not have the financial or other means to meet these requirements in any real sense. 
To be specific, issues that may present like lack of transportation to facilities in a more 
metropolitan area, whether the rehabilitation programs are covered by applicant’s 
insurance, whether applicant can afford co-pay for these programs, all serve to isolate the 
typical pre-authorization applicant or one who would need MAT the most. 
 Access to Buprenorphine seems to be no different. “The results of [the] survey 
[conducted by ASAM] and information obtained from secondary sources indicate that 21 
 
59 Id. 
  
states require a physician to certify that a patient either is attending or plans to attend 
counseling in order for a prior authorization for buprenorphine to be approved. At least 
another 9 states require very specific documentation of that counseling to be submitted, 
sometimes including requirements about who provides the counseling and whether or not 
that counseling is to be only by state approved counselors.” The extensive documentation 
process requires multiple doctors’ appointments and follow-ups, and is ultimately up to a 
physician’s discretion whether or not to certify. The extensive documentation process for 
counseling, and then transfer of those documents to the physician in charge, takes a lot of 
time from both the physician and the patient. This is time that is invaluable to the patient, 
who throughout the process, remains in need of treatment and assistance and can be at 
risk for relapse, overdose, and even death. 
 Time proves to be a repeated, overarching issue, regardless of the 
medication/MAT sought. If the applicant does not meet the criteria for pre-authorization 
at the time, they are forced to schedule an appointment for rehabilitation or psychological 
counseling which can take weeks, or wait the seven days without using opioids (a crucial 
time for relapse that can result in overdose or death). This does not account for the time it 
will take the form itself to process. The pre-authorization itself is time-sensitive, and 
there are periods for reauthorization for applicants. This means that many of the steps 
taken must be repeated each reauthorization period. 
 However, there is some hope. Many organizations and legislative forces are 
working to urge Medicaid programs to drop preauthorization altogether, or expedite the 
process as is more prevalent in commercial insurance programs. The AMA (American 
Medical Association) has proposed a bill modeled on Pennsylvania’s, where Governor 
  
Tom Wolf removed pre-authorization for MAT and persuaded outside insurers to do the 
same.60 “In addition to removing prior authorization for MAT in Medicaid and the 
commercial markets, the AMA model bill requires MAT to be on the lowest cost -sharing 
tier, extends MAT protections to correctional settings and includes provisions to 
strengthen oversight and enforcement of mental health and substance-use disorder parity 
laws.”61 This improvement would serve to reduce time wasted and resources between 
physicians and patients.  
  Additionally, “the President’s FY 2019 Budget includes a proposal that would 
require state Medicaid programs to cover all FDA-approved MAT for OUD, including 
associated counseling and other costs. These up-front investments in expanded MAT 
treatment are expected to reduce total Medicaid expenditures over time as more 
individuals recover from OUD; this provision would result in an estimated $865 million 
is savings over ten years.62 Hopefully, with an economic incentive in place as well, we 
may see a lean towards an adoption of some of AMA’s proposed goals. 
Also, “under current law, states are able to implement lock-in requirements for 
enrollees who have utilized Medicaid services at a frequency or amount that is not 
medically necessary, according to guidelines established by the state. These limitations 
may be imposed for “a reasonable period of time.” Almost all Medicaid agencies have a 
 
60 https://www.ama-assn.org/advocacy/patient-advocacy/quick-take-moves-cut-barriers-
opioid-use-disorder-treatment 
61 https://www.ama-assn.org/advocacy/patient-advocacy/quick-take-moves-cut-barriers-
opioid-use-disorder-treatment 
62 https://www.hhs.gov/about/agencies/asl/testimony/2018-04/tracking-opioid-and-
substance-use-disorders-medicare-medicaid-hhs-programs.html 
 
  
Lock-In or Patient Review and Restriction Program in which the state identifies potential 
fraud or misuse of controlled drugs by a beneficiary.63 While the lock-in programs don’t 
cut out the documentation barriers, they will most likely save a lot of money as a more 
efficient, computerized method.  
Strategies targeting opioid dependency and previous policy regarding MAT access 
have been cropping up in the past five years across many sources.  
“According to The U.S. Department of Health and Human Services, 
In April 2017, HHS outlined its five-point Opioid Strategy, which provides 
the overarching framework to leverage the expertise and resources of HHS 
agencies in a strategic and coordinated manner. The comprehensive, 
evidence-based Opioid Strategy aims to: 
• Improve access to prevention, treatment, and recovery support services to 
prevent the health, social, and economic consequences associated with 
opioid addiction and to enable individuals to achieve long-term recovery; 
• Target the availability and distribution of overdose-reversing medications 
to ensure the broad provision of these drugs to people likely to experience 
or respond to an overdose, with a particular focus on targeting high-risk 
populations; 
 
63 https://www.hhs.gov/about/agencies/asl/testimony/2018-04/tracking-opioid-and-
substance-use-disorders-medicare-medicaid-hhs-programs.html 
  
• Strengthen public health data reporting and collection to improve the 
timeliness and specificity of data and to inform a real-time public health 
response as the epidemic evolves; 
• Support cutting-edge research that advances our understanding of pain and 
addiction, leads to the development of new treatments, and identifies 
effective public health interventions to reduce opioid-related health harms; 
and 
• Advance the practice of pain management to enable access to high-
quality, evidence-based pain care that reduces the burden of pain for 
individuals, families, and society while also reducing the inappropriate use 
of opioids and opioid-related harms.64” 
With these efforts from AMA encouraging doctors to affect legislation and 
giving them the tools to do so, the presidential budget changes in 2019, and a few 
states spearheading the change in their Medicaid policies, there seems to be a bit 
of a turn for the more positive. At the very least, there appears to be a renewed 
social awareness to the paradoxical nature of preauthorization, and a less 
stigmatized regard for MAT overall.  
 
 
64 https://www.hhs.gov/about/agencies/asl/testimony/2018-04/tracking-opioid-and-
substance-use-disorders-medicare-medicaid-hhs-programs.html 
  
Pennsylvania as an Example 
Pennsylvania was and remains one of the highest-risk states when it came 
to opioid addiction, overdose, and fatality. In the past five years alone, 
Pennsylvania has been ranked one of the top 5 states with the highest opioid-
induced fatality rates.65 In fact, Pennsylvania decaled the opioid crisis a state of 
emergency only about two years ago which was described as one of the worst 
crises in the county.66 The crisis is ongoing.67 However, the state has made and is 
continuing to make active effort towards changing how opioid addiction is dealt 
with on a systemic level. “The state has gotten more people into treatment, they 
said, and lowered a key barrier that has long kept people with addiction from 
medication-assisted treatment, the “gold standard” of addiction treatment. It’s also 
begun, slowly, to expand access to those treatments to the state’s inmates, who are 
particularly vulnerable to substance-use disorder, and relapse and overdose upon 
their release.”68 The state initiated a drug-treatment hotline, which received over 
15,000 calls within its first year of operation, and almost half of whose callers 
were immediately connected with treatment. 
One of the more groundbreaking achievements occurred just about a year 
ago when the state of Pennsylvania eliminated the Pre-authorization process for 
 
65 https://www.philly.com/philly/health/addiction/dea-fatal-ods-rose-37-across-pa-in-
2016-20170608.html 
66 https://www.philly.com/health/opioid-crisis-update-progress-pennsylvania-overdoses-
addiction-20190107.html 
67 Id. 
68 Id.  
 
  
MAT medications under Medicaid altogether.69 The widespread Medicaid change 
prompted for-profit insurance companies to do the same, with many dropping prior 
authorization for MAT medications to be able to compete with Medicaid. 70 
“In addition to removing this unnecessary restriction on treatment, insurers 
have also committed to including a comprehensive range of medications to treat 
substance use disorders on the lowest cost-sharing tier of a health plan’s pharmacy 
benefit as part of this agreement.”71 Additionally, since then, Pennsylvania has 
opened almost fifty more treatment facilities specific to opioid users to help 
coordinate help and treatment.72 “Before these “centers of excellence” opened, about 48 
percent of such patients were receiving addiction treatment. Now, 70 percent of that 
population has sought addiction treatment, and 60 percent stayed in treatment past 30 
days.”73  This is a significant improvement, and Pennsylvania is now directing its focus to 
ensuring that those who receive treatment continue on the road to recovery.74  
Pennsylvania serves as an example of what lifting the prior authorization 
requirement has done and the effect it can have if adopted nationwide. “‘With this 
requirement lifted for a preferred buprenorphine agent, significantly less administrative 
time is spent completing forms, attaching chart notes and compiling results to submit to 
insurance companies, as well as monitoring when prior authorizations need to be 
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71 https://www.ama-assn.org/press-center/press-releases/pennsylvania-removes-prior-
authorization-opioid-treatment 
72 Id. 
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renewed,’ [David O'Gurek, M.D., of Philadelphia] told AAFP News. And time saved 
translates to lives saved. 
‘For every delay, every lack of completion of review in the timeframe, every fax that 
apparently got lost and was never received,’ O'Gurek said, ‘individuals struggling with 
opioid-use disorder were at risk for relapse, overdose or death.’”75 
 Prior authorization is one of many barriers in access to one of the most provenly 
effective treatments of a crisis that has faced America for decades. Dating back to before 
the civil war, opioids have always been a concern. It is only now that we have the tools to 
effectively treat those who suffer addiction or dependency. With a little attention to 
continuing health and recovery in individuals and less time spent on paperwork and 
authorization, which can isolate those who need the treatment the most, states with high 
fatality rates may see some change. 
 
 
75 https://www.aafp.org/news/government-medicine/20181120pennpriorauth.html 
